Economists Warn Of Costs If Medicare Covers New Obesity Drugs

The cost of expanding U.S. Medicare prescription drug coverage to pay for expensive, new obesity medications could be catastrophic, health economists warned in a report published on Saturday.

Big-selling diabetes drugs have been repurposed as obesity treatments after demonstrating weight loss of more than 20% in clinical trials. While they are far more effective than older drugs, lifetime use might be required to keep lost weight off.

Once-weekly injections of Novo Nordisk’s (NOVOb.CO) Wegovy, for example, cost more than $13,000 per year in the U.S. after rebates and discounts. Mounjaro from Eli Lilly and Co (LLY.N), expected to gain U.S. approval for obesity next year, retails at $1,540 for a one-month supply for diabetes.

Presently, Medicare is forbidden by law from paying for antiobesity prescriptions. But should the bipartisan The Treat and Reduce Obesity Act get reintroduced and passed by Congress, Medicare will be compelled to cover drugs for weight loss.

Health economists writing in The New England Journal of Medicine estimate that if 10% of Medicare recipients with obesity diagnoses used prescription weight loss drugs, annual part D spending would be $26.8 billion for Wegovy compared with $1.32 billion for a generic version older Qysmia from Vivus Inc.

That amounts to nearly 20% of the total 2019 Medicare Part D spending, Khrysta Baig of Vanderbilt University School of Medicine and colleagues said.

“The burden of obesity and obesity-related conditions is unquestionably high, but the value of Medicare coverage of antiobesity medications remains unclear,” they said, adding that more research is needed to know whether weight loss induced by these drugs translates to better long-term health outcomes.

The Medicare health program covers more than 60 million Americans, most over age 65. The authors point out that many people in the program have already incurred the health problems associated with long-term obesity, unlike younger populations typically included in clinical trials.

Obesity prevalence in the United States is 41.5% among adults aged 60 and older, according to the Centers for Disease Control and Prevention.

The influential Institute for Clinical and Economic Review (ICER) has said the annual price of Wegovy would need to decrease to $7,500 to $9,700 for it to be cost effective compared with lifestyle modification alone. Even at that price range, it still would not be cost-effective compared with generic Qysmia, ICER said.

“Given the outstanding questions about the benefits of these drugs for Medicare beneficiaries, it would be prudent for Congress and CMS (the Centers for Medicare & Medicaid Services) to fully consider tradeoffs before passing legislation of this magnitude,” Baig said.

 

Source Link

Recommended Articles

CMS Distributes $10B To Strengthen Rural Health Care Access

The Centers for Medicare & Medicaid Services will distribute $10 billion among all 50 states during the second year of the Rural Health Transformation Program. This funding is intended to build on early progress and deliver lasting improvements in access, quality and health outcomes for rural Americans. “President Trump made a historic investment in rural ...

Read More

What Your Health Benefits Advisor Wishes You Knew Before Choosing A Plan

A family can pay their health insurance premium every month and still hesitate to see a doctor because of what the visit might cost. Or worse, an employee may believe the plan they chose through their company covers a specialist, only to learn it does not once they are at the provider’s office. Misunderstandings can ...

Read More

Feds Invite Industry To Test Electronic Prior Auth Readiness

The federal government is inviting health insurance companies, hospitals and electronic health record companies to test their readiness for upcoming electronic prior authorization requirements. The Office of the National Coordinator for Health Information Technology, the Health and Human Services Department and the Centers for Medicare and Medicaid Services announced Thursday they will hold voluntary 10-12 ...

Read More

Google Cloud Rolls Out Gemini For Healthcare

Google launched Tuesday Gemini for healthcare, an agentic artificial intelligence platform aimed at connecting complex clinical, financial and administrative workflows used by healthcare providers and payers. The platform was developed alongside clinical and health plan leaders and is built to support HIPAA compliance, the tech giant said. “The fundamental challenge in healthcare isn’t a lack ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square